TABLE 2

In vitro interactions of micafungin with fluconazole and voriconazole against Candida auris

Strain no.MFG + FLUcMFG + VRCc
MIC (μg/ml)FICI/INTMIC (μg/ml)FICI/INT
MFGFLUMFG/FLUMFGVRCMFG/VRC
VPCI 482/P/13a0.25≥640.25/641.5/IND0.2520.016/0.50.31/SYN
VPCI 1132/P/13a0.5320.25/40.62/IND0.50.50.016/0.1250.28/SYN
VPCI 1133/P/13a,b8≥644/320.75/IND812/0.250.5/SYN
VPCI 265/P/14a0.5320.5/81.25/IND0.580.063/10.25/SYN
VPCI 1510/P/14a0.125320.063/80.75/IND0.12540.016/0.250.19/SYN
VPCI 1514/P/14a,b8≥648/161.12/IND80.51/0.1250.37/SYN
VPCI 266/P/14a0.25≥640.25/321.25/IND0.250.50.008/0.1250.28/SYN
VPCI 267/P/14a,b8328/81.25/IND80.51/0.1250.37/SYN
VPCI 487/P/14a4≥644/321.25/IND410.5/0.1250.25/SYN
VPCI 518/P/14a0.5≥640.25/641/IND0.510.016/0.1250.15/SYN
  • a Fluconazole-resistant isolates (n = 10).

  • b Micafungin-resistant isolates (n = 3).

  • c MFG, micafungin; FLU, fluconazole; VRC, voriconazole; FICI, fractional inhibitory concentration index; IND, indifference; SYN, synergy; INT, interpretation.